Literature DB >> 18710389

Reduction of B cell turnover in chronic lymphocytic leukaemia.

Julien Defoiche1, Christophe Debacq, Becca Asquith, Yan Zhang, Arsène Burny, Dominique Bron, Laurence Lagneaux, Derek Macallan, Luc Willems.   

Abstract

Whether chronic lymphocytic leukaemia (CLL) is a latent or a proliferating disease has been intensively debated. Whilst the dogma that CLL results from accumulation of dormant lymphocytes is supported by the unresponsiveness of leukaemic cells to antigens and polyclonal activators, recent in vivo kinetic measurements indicate that B lymphocytes do divide at significant rates in CLL. However, an important and still unanswered question is whether CLL cells proliferate faster or slower compared with their normal counterparts. This report addressed directly this point and compared B-cell kinetics in CLL subjects and healthy controls, using a pulse-chase approach based on incorporation of deuterium from 6,6-(2)H(2)-glucose into DNA. We confirmed that B cells proliferated at significant levels in CLL but found that the proliferation rates were reduced compared with healthy subjects (mean 0.47 vs. 1.31%/d respectively, P = 0.007), equivalent to an extended doubling time of circulating B cells (147 d vs. 53 d). In conclusion, CLL B cells proliferate at reduced levels compared with healthy controls. CLL is thus characterized by an aberrant B-cell kinetics with a decrease in cell turnover, an observation that may impact on elaboration of efficient therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18710389     DOI: 10.1111/j.1365-2141.2008.07348.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

1.  RNA virus microRNA that mimics a B-cell oncomiR.

Authors:  Rodney P Kincaid; James M Burke; Christopher S Sullivan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

Review 2.  Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells.

Authors:  Rajendra N Damle; Carlo Calissano; Nicholas Chiorazzi
Journal:  Best Pract Res Clin Haematol       Date:  2010-03       Impact factor: 3.020

3.  AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.

Authors:  Basile Stamatopoulos; Nathalie Meuleman; Cécile De Bruyn; Karlien Pieters; Philippe Mineur; Christine Le Roy; Stéphane Saint-Georges; Nadine Varin-Blank; Florence Cymbalista; Dominique Bron; Laurence Lagneaux
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

4.  Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin.

Authors:  Charles C Chu; Rosa Catera; Lu Zhang; Sebastien Didier; Briana M Agagnina; Rajendra N Damle; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

5.  Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk.

Authors:  Dirk Winkler; Christof Schneider; Manuela Zucknick; Daniela Bögelein; Kerstin Schulze; Thorsten Zenz; Julia Mohr; Angela Philippen; Henriette Huber; Andreas Bühler; Annett Habermann; Axel Benner; Hartmut Döhner; Stephan Stilgenbauer; Daniel Mertens
Journal:  Haematologica       Date:  2010-08-16       Impact factor: 9.941

6.  Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease.

Authors:  Amit K Mittal; Nagendra K Chaturvedi; Karan J Rai; Christine E Gilling-Cutucache; Tara M Nordgren; Margaret Moragues; Runqing Lu; Rene Opavsky; Greg R Bociek; Dennis D Weisenburger; Javeed Iqbal; Shantaram S Joshi
Journal:  Mol Med       Date:  2014-07-15       Impact factor: 6.354

7.  A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency.

Authors:  Mariam Hammadi; Jacques-Olivier Pers; Christian Berthou; Pierre Youinou; Anne Bordron
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

8.  Measurement of proliferation and disappearance of rapid turnover cell populations in human studies using deuterium-labeled glucose.

Authors:  Derek C Macallan; Becca Asquith; Yan Zhang; Catherine de Lara; Hala Ghattas; Julien Defoiche; Peter C L Beverley
Journal:  Nat Protoc       Date:  2009-08-20       Impact factor: 13.491

9.  Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes.

Authors:  J B Bollyky; S A Long; M Fitch; P L Bollyky; M Rieck; R Rogers; P L Samuels; S Sanda; J H Buckner; M K Hellerstein; C J Greenbaum
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

10.  Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL) for analysis of cell proliferation: validation of a simplified method suitable for multi-center clinical studies.

Authors:  Gregory M Hayes; Robert Busch; Jason Voogt; Iche M Siah; Tracy A Gee; Marc K Hellerstein; Nicholas Chiorazzi; Kanti R Rai; Elizabeth J Murphy
Journal:  Leuk Res       Date:  2009-10-24       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.